Talisuna AO, Bloland P, DāAlessandro U, 2004. History, dynamics and public health importance of malaria parasite resistance. Clin Microbiol Rev 17 :235ā254.
Attaran A, Barnes KI, Curtis C, DāAlessandro U, Fanello CI, Galinski MR, Kokwaro G, Looareesuwan S, Makanga M, Mutabingwa TK, Talisuna A, Trape JF, Watkins WM, 2004. WHO, the Global Fund, and medical malpractice in malaria treatment. Lancet 363 :237ā240.
World Health Organization, 2006. Guidelines for the Treatment of Malaria. Global Malaria Programme. Geneva: World Health Organization, WHO/HTM/MAL/ 2006: 1108.
Bosman A, Mendis KN, 2007. A major transition in malaria treatment: the adoption and deployment of artemisinin-based combination therapies. Am J Trop Med Hyg 77 (Suppl 6):193ā197.
Shretta R, Omumbo J, Rapuoda BA, Snow RW, 2000. Using evidence to change antimalarial drug policy in Kenya. Trop Med Int Health 5 :755ā764.
Williams HA, Durrheim DN, Shretta R, 2004. The process of changing national malaria treatment policy: lessons from country level studies. Health Policy Plan 19 :356ā370.
Amin AA, Zurovac D, Kangwana BB, Greenfield J, Otieno DN, Akhwale WS, Snow RW, 2007. The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya. Malar J 6 :72.
Njogu J, Akhwale W, Hamer DH, Zurovac D, 2008. Health facility and health worker readiness to deliver new national treatment policy for malaria in Kenya. East Afr Med J 85 :213ā221.
Zurovac D, Ndhlovu M, Sipilanyambe N, Chanda P, Hamer DH, Simon JL, Snow RW, 2007. Paediatric malaria case-management with artemether-lumefantrine in Zambia: a repeat cross-sectional study. Malar J 6 :31.
Zurovac D, Tibenderana JK, Nankabirwa J, Ssekitooleko J, Njogu JN, Rwakimari JB, Meek S, Talisuna A, Snow RW, 2008. Malaria case-management under artemether-lumefantrine treatment policy in Uganda. Malar J 7 :181.
Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 26 | 26 | 7 |
Full Text Views | 418 | 85 | 0 |
PDF Downloads | 85 | 13 | 0 |
A key bench mark of successful therapeutic policy implementation, and thus effectiveness, is that the recommended drugs are available at the point of care. Two years after artemether-lumefathrine (AL) was introduced for the management of uncomplicated malaria in Kenya, we carried out a cross-sectional survey to investigate AL availability in government facilities in seven malaria-endemic districts. One of four of the surveyed facilities had none of the four AL weight-specific treatment packs in stock; three of four facilities were out of stock of at least one weight-specific AL pack, leading health workers to prescribe a range of inappropriate alternatives. The shortage was in large part caused by a delayed procurement process. National ministries of health and the international community must address the current shortcomings facing antimalarial drug supply to the public sector.
Talisuna AO, Bloland P, DāAlessandro U, 2004. History, dynamics and public health importance of malaria parasite resistance. Clin Microbiol Rev 17 :235ā254.
Attaran A, Barnes KI, Curtis C, DāAlessandro U, Fanello CI, Galinski MR, Kokwaro G, Looareesuwan S, Makanga M, Mutabingwa TK, Talisuna A, Trape JF, Watkins WM, 2004. WHO, the Global Fund, and medical malpractice in malaria treatment. Lancet 363 :237ā240.
World Health Organization, 2006. Guidelines for the Treatment of Malaria. Global Malaria Programme. Geneva: World Health Organization, WHO/HTM/MAL/ 2006: 1108.
Bosman A, Mendis KN, 2007. A major transition in malaria treatment: the adoption and deployment of artemisinin-based combination therapies. Am J Trop Med Hyg 77 (Suppl 6):193ā197.
Shretta R, Omumbo J, Rapuoda BA, Snow RW, 2000. Using evidence to change antimalarial drug policy in Kenya. Trop Med Int Health 5 :755ā764.
Williams HA, Durrheim DN, Shretta R, 2004. The process of changing national malaria treatment policy: lessons from country level studies. Health Policy Plan 19 :356ā370.
Amin AA, Zurovac D, Kangwana BB, Greenfield J, Otieno DN, Akhwale WS, Snow RW, 2007. The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya. Malar J 6 :72.
Njogu J, Akhwale W, Hamer DH, Zurovac D, 2008. Health facility and health worker readiness to deliver new national treatment policy for malaria in Kenya. East Afr Med J 85 :213ā221.
Zurovac D, Ndhlovu M, Sipilanyambe N, Chanda P, Hamer DH, Simon JL, Snow RW, 2007. Paediatric malaria case-management with artemether-lumefantrine in Zambia: a repeat cross-sectional study. Malar J 6 :31.
Zurovac D, Tibenderana JK, Nankabirwa J, Ssekitooleko J, Njogu JN, Rwakimari JB, Meek S, Talisuna A, Snow RW, 2008. Malaria case-management under artemether-lumefantrine treatment policy in Uganda. Malar J 7 :181.
Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 26 | 26 | 7 |
Full Text Views | 418 | 85 | 0 |
PDF Downloads | 85 | 13 | 0 |